Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07382661
Starting soon Phase 1

Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin

NCT07382661 · tracked via the Priya Life Science South Korea tracker
Sponsor
Daewon Pharmaceutical Co., Ltd
Phase
Phase 1
Started
2026-02
Last updated
2026-02-04

Condition(s) studied

Healthy Adult Volunteers

Investigational drug(s) / intervention(s)

DW4421 →DW4421-1DW4421-2

DW4421: 1 tablet will be orally administered

DW4421-1: 2 capsules will be orally administered

DW4421-2: 1 tablet will be orally administered

Study summary

Drug-Drug Interaction between DW4421 and Amoxicillin/Clarithromycin

Eligibility

Sex
ALL
Min age
19 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Inclusion Criteria: * Healthy adult aged 19 to 50 (inclusive) years, at the time of screening. * Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg/m2 (inclusive) at screening visit. Exclusion Criteria: * Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history.

Primary outcome measure(s)

  • Cmax,ss: Maximum concentration of DW4421, DW4421-1 and DW4421-2 at steady state — Up to day 6 or day 7
  • AUCτ,ss: Area under the drug concentration-time curve of DW4421, DW4421-1, DW4421-2 within a dosing interval at steady state — Up to day 6 or day 7

Trial sites (1)

FacilityCityRegionStatus
Chungbuk National University Hospital Cheongju-si North Chungcheong

More Daewon Pharmaceutical Co., Ltd. trials in South Korea

Multiple Ascending Dose Study of DW4421 Starting soon
Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers Starting soon
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers Starting soon
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers Enrolling by invitation
Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma Recruiting

Other trials for the same condition

Multiple Ascending Dose Study of DW4421 Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07382661 on ClinicalTrials.gov ↗ ← All trials in South Korea